The Tet Technology is the most widely used technology to control gene expression as documented by:

• More than 7,087 scientific publications as of 05/2010

• More than 1,500 accounts at Clontech alone, serving both academic and commercial customers

• Since 1996, more than 150 organisations have licensed the Tet Technology

• 17 out of the top 20 pharmaceutical companies based on their netsales in 2006 are currently licensees

• The Tet IP Portfolio comprises 35 issued patents and 18 pending patent applications, respectively, organised in 6 patent families

• The Tet IP portfolio relates to  the original and improved versions of transcriptional activators,  silencers, responsive elements and  chromosomal loci for transgenesis

• The Tet Technology is patent protected in North-America, Europe, Japan and Australia